• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

临床输血与检验 ›› 2020, Vol. 22 ›› Issue (6): 627-632.DOI: 10.3969/j.issn.1671-2587.2020.06.017

• 临床研究 • 上一篇    下一篇

强化清髓单份非血缘脐血移植治疗FLT3-ITD突变阳性急性髓系白血病疗效观察*

吴月, 朱小玉, 刘会兰, 宋闿迪, 汤宝林, 孙自敏   

  1. 230001 合肥,中国科学技术大学附属第一医院血液内科
  • 收稿日期:2020-10-13 出版日期:2020-12-20 发布日期:2021-01-18
  • 通讯作者: 汤宝林,男,副主任医师,硕士,主要从事血液学相关研究,(E-mail)zwcrystalbl@163.com。
  • 作者简介:吴月(1990-),女,医师,硕士,主要从事血液学相关研究,(E-mail)287109658@qq.com。
  • 基金资助:
    *本课题受国家自然科学面上基金(No.81670165)、2018年科大新医学联合基金项目(No.WK9110000020)资助

Curative Efficacy of Unrelated Donor Single-unit Umbilical Cord Blood Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia

WU Yue, ZHU Xiao-yu, LIU Hui-lan, et al   

  1. Hematology Department,The First Affiliated Hospital of USTC,Hefei 230001
  • Received:2020-10-13 Online:2020-12-20 Published:2021-01-18

摘要: 目的 回顾性分析采用强化清髓性预处理方案的单份非血缘脐血移植(sUCBT)治疗FLT3-ITD突变阳性急性髓系白血病(AML)的疗效。方法 2012年6月~2018年12月中国科学技术大学附属第一医院(安徽省立医院)血液科共22例FLT3-ITD突变阳性AML患者进行强化清髓性不含抗胸腺球蛋白(ATG)预处理方案的UCBT。其中患者男12例,女10例。中位年龄24(4~53)岁,中位体重58(15~77)kg。其中6例患者伴NPM1突变阳性,移植前处于第一次完全缓解期(CR1)的患者12例,CR2期3例,疾病进展期7例。所有患者接受强化清髓预处理方案,全身照射/环磷酰胺/阿糖胞苷(TBI/Cy/Ara-C)4例,白消安/环磷酰胺/氟达拉滨(BU/Cy/Flu)15例,BU/Cy/Ara-C 3例,预防移植物抗宿主病(GVHD)的方案为环孢素A联合吗替麦考酚酯(MMF),不含ATG。结果 20/22例患者获得造血重建,42 d中性粒细胞累积植入率为90.9%,中位植入时间为17.5(11~25)d,120 d血小板累积植入率为84.6%,中位植入时间为37(20~68)d。移植相关并发症:13/22(59.1%)例患者出现植入前综合征,12例患者出现II-IV°急性GVHD,累积发生率为54.5%,6例患者出现III-IV°急性GVHD,累积发生率为27.3%,4例患者出现局限性皮肤慢性GVHD,720 d累积发生率为18.2%,无广泛型cGVHD发生。截至2020年6月30日,中位随访时间747.5(6~2 932)d,3例患者出现原发病复发,3年累积复发率为13.6%,3年总生存率(OS)和无病生存率(DFS)分别为62.9%和63.6%。结论 强化清髓sUCBT治疗FLT3-ITD突变阳性AML初步结果显示疗效较好,值得推广应用。

关键词: 急性髓系白血病, FLT3-ITD突变, 非血缘脐血造血干细胞移植

Abstract: Objective We conducted a retrospective study to evaluate the efficacy of intensified myeloablative conditioning regimen for unrelated donor single-unit umbilical cord blood transplantation (sUCBT) in acute myeloid leukemia with FLT3-ITD mutation.Methods We studied a total of 22 patients with FLT3-ITD positive acute myeloid leukemia undergoing sUCBT between Jun 2012 and Dec 2018 at hematology department, the first affiliated hospital of USTC(Anhui provincial hospital), and evaluated the therapeutic efficacy of intensified myeloablative conditioning regimen without antithymocyte globulin (ATG). Twelve males and 10 females were enrolled. Median age was 24 years (range 4-53) and median weight was 58 kg (range 15-77). Among them, 6 of the patients had NPM1 mutation. Twelve patients were in first complete remission (CR1), three in second complete remission (CR2), and seven in advanced-stage disease before transplantation. All patients received intensified myeloablative conditioning regimen. Four received total body irradiation/ cyclophosphamide/cytosine arabinoside (TBI/Cy/Ara-C). Fifteen received Busulfan/ cyclophosphamide/fludarabine(BU/Cy/Flu). Three received BU/Cy/Ara-C. Ciclosporin A (CsA) in combination with mycophenolate mofetil (MMF) without ATG was used approach to graft-versus-host disease (GVHD) prevention.Results Hematopoietic reconstitution had been achieved successfully in 20/22 patients. The cumulative incidence (CI) of neutrophil engraftment at 42 days was 90.9%, and the median time to engraftment was 17.5 days (range 11~25 days). The CI of platelet engraftment at 120 days was 84.6%, and the median time to engraftment was 37 days (range 20~68 days). Transplant-related complications were collected. Thirteen (59.1%) patients developed pre-engraftment syndrome (PES). Twelve had grade II-IV acute GVHD, and the CI was 54.5%. Six had grade III-IV acute GVHD, and the CI was 27.3%. Four had localized cutaneous chronic GVHD (cGVHD), and the CI at 720 days was 18.2%. No extensive cGVHD occurred. As of June 30, 2020, a median follow-up of 747.5 days(range 6-2 932). Three patients had primary recurrence. The 3-year CI of relapse was 13.6%. The 3-year overall survival and disease-free survival were 62.9% and 63.6% respectively.Conclusion The preliminary investigation of sUCBT with intensified myeloablative conditioning regimen for FLT3-ITD mutation acute myeloid leukemia showed good curative effect, and It is worthy to apply.

Key words: Acute myeloid Leukemia, FLT3-ITD mutation, Umbilical cord blood transplantation

中图分类号: